Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis

Kinoshita, Kohji; Limuro, Yuji; Fujimoto, Jiro; Inagaki, Yutako; Namikawa, Kazuhiko; Kiyama, Hiroshi; Nakajima, Yuji; Otogawa, Kohji; Kawada, Norifumi; Friedman, Scott L.; Ikeda, Kazuo
March 2007
Gut;Mar2007, Vol. 56 Issue 3, p396
Academic Journal
Background: Activated hepatic stellate cells (HSCs) are an attractive target for antifibrotic therapy based on their key role in extracellular matrix accumulation during liver injury. Aim : To develop a system for regulable and cell-specific gene expression in HSCs to enable targeted delivery of therapeutic genes. Method: Two types of recombinant adenoviral vectors were constructed, one expressing the Cre gene under the surveillance of specific promoters and the other containing a potent expression unit that was activated by Cre recombinase-mediated recombination to remove an upstream lox-flanked ‘stuffer’ sequence, thereby amplifying the expression of downstream transgene of interest while maintaining specificity. Results: When the promoter of the collagen 1A2 gene drove Cre recombinase expression in primary quiescent rat HSC, modest green fluorescence protein (GFP) expression was observed. However, in activated HSC, the collagen promoter effectively drove Cre recombinase activity, as assessed by the increased expression of GFP. In contrast, GFP expression was barely observed when the collagen promoter was expressed in hepatocytes. HSC-specific expression of Smad7 considerably reduced the expression of type I collagen in culture and decreased fibrosis in two liver fibrosis models. Finally, to achieve targeted clearance of activated HSC in culture and in vivo, thymidine kinase was selectively expressed under the control of the collagen promoter, which conferred cell-specific killing by ganciclovir leading to reduced fibrosis. Conclusion: Our results show the potential utility of transcriptionally controlled gene therapy using a Cre/loxP system to ameliorate hepatic fibrosis in vivo.


Related Articles

  • Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand. Jiang Li; Kuruba, Ramalinga; Wilson, Annette; Xiang Gao; Yifei Zhang; Song Li // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Activation of hepatic stellate cells (HSCs) plays an important role in the development of cirrhosis through the increased production of collagen and the enhanced contractile response to vasoactive mediators such as endothelin-1 (ET-1). The farnesoid X receptor (FXR) is a member of the nuclear...

  • Fibrogénesis hepática. Páramo Hernández, David B.; Regino, William Otero; Pineda Ovalle, Luis F. // Revista Colombiana de Gastroenterología;Jun2010, Vol. 25 Issue 2, p187 

    Progress achieved in chronic liver disease treatment has also generated increased interest in clarifying the mechanisms underlying the development of hepatic fibrosis. After a liver injury activation of hepatic stellate cells (HSC) and their conversion to contractile, proliferative and...

  • TNFR1-mediated signaling is important to induce the improvement of liver fibrosis by bone marrow cell infusion. Hisanaga, Takuro; Terai, Shuji; Iwamoto, Takuya; Takami, Taro; Yamamoto, Naoki; Murata, Tomoaki; Matsuyama, Toshifumi; Nishina, Hiroshi; Sakaida, Isao // Cell & Tissue Research;Oct2011, Vol. 346 Issue 1, p79 

    The importance of TNF-α signals mediated by tumor necrosis factor receptor type 1 (TNFR1) in inflammation and fibrosis induced by carbon tetrachloride (CCl), and in post-injury liver regeneration including a GFP/CCl model developed as a liver repair model by bone marrow cell (BMC) infusion,...

  • TGF-β in progression of liver disease. Dooley, Steven; Dijke, Peter // Cell & Tissue Research;Jan2012, Vol. 347 Issue 1, p245 

    Transforming growth factor-β (TGF-β) is a central regulator in chronic liver disease contributing to all stages of disease progression from initial liver injury through inflammation and fibrosis to cirrhosis and hepatocellular carcinoma. Liver-damage-induced levels of active TGF-β...

  • Prognostic Value of Hepatocyte Proliferative Activity After Transjugular Intrahepatic Portosystemic Shunt. Delhaye, Myriam; Le Moine, Olivier; Degraef, Chantal; Devière, Jacques; Galand, Paul // American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1866 

    OBJECTIVES: Previous data indicated that the proliferating cell nuclear antigen-labeling index (PCNA-LI) reflects the liver functional reserve in human liver cirrhosis. The aim of the study was to evaluate the hepatocyte proliferative activity as a marker for the outcome of patients after...

  • Macroregenerative Nodules of the Liver in Primary Biliary Cirrhosis: Report of Two Autopsy Cases. Terada, Tadashi; Kurumaya, Hiroshi; Nakanuma, Yasuni; Hayakawa, Yasuhiro; Matsuda, Hiroto // American Journal of Gastroenterology;Apr1989, Vol. 84 Issue 4, p418 

    Recently, macroregenerative nodules of the liver have been regarded as putative precancerous lesions in human cirrhotic livers. We describe the morphologies of two macroregenerative nodules, one benign and another harboring a malignant hepatocellular focus, occurring in two patients with primary...

  • Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Jianghong Fan; Xin Li; Ping Li; Ning Li; Tailing Wang; Hong Shen; Yaw Siow; Choy, Patrick; Yuewen Gong // Biochemistry & Cell Biology;Apr2007, Vol. 85 Issue 2, p189 

    Treatment of liver fibrosis and cirrhosis remains a challenging field. Hepatocyte injury and the activation of hepatic stellate cells are the 2 major events in the development of liver fibrosis and cirrhosis. It is known that several Chinese herbs have significant beneficial effects on the...

  • Cirrhosis.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p253 

    Provides information on cirrhosis. Causes; Assessment and diagnosis; Pathophysiology; Diagnosis; Treatment.

  • Liver fibrogenesis in non-alcoholic steatohepatitis. Zhaolian Bian; Xiong Ma // Frontiers in Physiology;Jul2012, Vol. 3, p1 

    Non-alcoholic fatty liver disease (NAFLD) is emerging as one of the most common chronic liver diseases in developed western countries. Non-alcoholic steatohepatitis (NASH) is the most severe form of NAFLD, and can progress to more severe forms of liver disease, including fibrosis, cirrhosis, and...


Read the Article


Sign out of this library

Other Topics